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Abstract
We examined the prevalence of reported pain following human papillomavirus (HPV) vaccination
and whether it differed from that for other adolescent vaccines or affected completion of the HPV
vaccine regimen. In 2008, we conducted cross-sectional surveys with parents of adolescent girls
aged 11–20 living in areas of North Carolina with elevated cervical cancer rates who had received
at least one dose of HPV vaccine. Pain from HPV vaccination, while commonly reported by
parents, was less frequent compared to other adolescent vaccines and did not appear to affect
vaccine regimen completion. These findings may be important to increase HPV vaccination
coverage.
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1. Introduction
Human papillomavirus (HPV) vaccine uptake remains modest among eligible females in the
US. In recent large studies, only about 25% of adolescent girls had initiated HPV vaccine by
early 2008, with even fewer having completed the full three-dose regimen [1,2]. Parents are
less likely to get HPV vaccine for their adolescent daughters if they are concerned about
adverse events following vaccination [3]. For this reason, anecdotal accounts and national
media coverage of HPV vaccine side effects, such as unusually high rates of pain at the
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injection site and syncope (i.e., fainting), are of serious concern [4–6]. Understanding
reported side effects of HPV vaccine is important for fostering widespread vaccine
initiation.
In clinical trials of the quadrivalent HPV vaccine, which is currently licensed for clinical use
in the US, about 84% of participants reported experiencing some pain after vaccination, with
pain after any one dose ranging from 61% to 63% [7]. Additional clinical studies showed
similar rates of pain [8,9]. Although syncope following vaccination is of particular concern
because it is especially common among adolescents and young adults [10,11], syncope after
HPV vaccination does not appear to be abnormally high. Data on over 350,000 HPV vaccine
doses from Vaccine Safety Datalink (VSD), an active vaccine safety surveillance system in
the US, showed no evidence of increased risk of syncope following HPV vaccination,
compared to other vaccines administered to adolescents and young adults [12]. Furthermore,
almost all cases of syncope reported to the US Vaccine Adverse Event Reporting System
(VAERS), a passive surveillance system, have been classified as nonserious [13].
No published studies, to our knowledge, have compared pain reports for HPV vaccine and
other vaccines. In this study, we interviewed caregivers of adolescent females about pain
and syncope their daughters may have experienced following HPV vaccination and other
adolescent vaccines. We also examined whether reported HPV vaccine-related pain was
associated with completion of the three-dose vaccination series. We acknowledge that our
study relies on parental recall of daughters' vaccination experiences, which may be subject
to error. However, we believe our results still provide important insight into how side effects
from HPV vaccine compare to those from other adolescent vaccines.
2. Materials and methods
2.1. Study design
Caregivers of adolescent girls participated in a longitudinal study investigating HPV vaccine
decision making, as described in detail by Brewer et al. [14]. In brief, interviewers contacted
a probability sample of households in five North Carolina counties using random-digit-
dialing (5%) or a non-overlapping targeted-list frame of directory-listed residential
telephone numbers with available recent household demographic information (95%). They
oversampled households likely to contain an adolescent female in the targeted age range of
10–18 years old, households likely to be African American, and rural telephone exchanges
[15]. Trained personnel used computer-assisted telephone interviewing equipment to
conduct interviews with caregivers, who we refer to as parents for the remainder of this
report.
Of 1220 eligible parents contacted, 889 (73%) completed baseline interviews between July
and October 2007 [16]. Of 873 baseline respondents eligible for follow-up, 650 (74%)
completed follow-up interviews between October and November 2008 [14]. This report
includes cross-sectional data from parents who reported during the follow-up interview that
their daughters had received one or more doses of HPV vaccine (n = 229).
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Many of these parents also reported their daughters had received a tetanus booster vaccine
(90%, 206/229) or meningococcal vaccine (50%, 115/229) at some point prior to the follow-
up interview. Most parents were female (95%), non-Hispanic white (77%) or non-Hispanic
African American (17%), married (86%), and had at least some college education (87%)
(Table 1). The Institutional Review Board at the University of North Carolina approved the
study.
2.2. Measures
Interviewers asked parents to report the level of pain or discomfort, if any, their daughters
experienced from any HPV vaccine doses (1) while in the doctor's office (time of injection)
and (2) in the hours and days afterwards. Response options were “no pain or discomfort,”
“mild,” “moderate,” “severe pain or discomfort,” “daughter didn't say,” and “don't know.”
We selected these responses to be consistent with measures reported in clinical trials of HPV
vaccine and other vaccines [7,17,18]. When parents reported any pain for the hours and days
after injection, interviewers asked how long the pain persisted. Interviewers assessed
syncope by asking parents if their daughters experienced a problem with dizziness or
fainting following HPV vaccination.
Interviewers assessed pain or discomfort from two other recommended adolescent vaccines,
meningococcal vaccine and tetanus booster vaccine (including tetanus and diphtheria [Td]
vaccine; and tetanus, diphtheria, and acellular pertussis [Tdap] vaccine), for both the time of
injection and in the hours and days afterwards. Response scales were identical to those for
HPV vaccine. Tetanus booster (one-dose regimen) and meningococcal (one-dose regimen)
vaccines were ideal comparisons since the age recommendations for these vaccines are
similar to those for HPV vaccine [19].
Pain levels (no pain, mild, moderate, or severe pain) reported for HPV vaccine at each time
period were compared with those reported for tetanus booster and meningococcal vaccines.
We created “pain level comparison” variables that had three levels: (1) “same level of pain”
reported for HPV vaccine and the comparison vaccine, (2) “less pain from HPV vaccine”,
and (3) “more pain from HPV vaccine.” If a parent responded “daughter didn't say” or “don't
know” to either pain question necessary for a comparison, we did not use their data. We also
created six dichotomous pain variables (three vaccines and two time periods) with values of
0 for no pain and 1 for any pain (mild, moderate, or severe), not using responses of
“daughter didn't say” and “don't know.”
Interviewers asked parents to compare the pain or discomfort associated with HPV vaccine
to pain or discomfort associated with all other vaccines their daughters had received.
Response options were “less pain or discomfort,” “about the same,” “more pain or
discomfort,” “does not apply/no shots to compare to,” and “don't know.”
Parents reported how many doses of HPV vaccine their daughters had received and when
they received each one. We defined completion of the HPV vaccine regimen as receipt of all
three HPV vaccine doses or receipt of only one or two doses but still on-schedule to
complete the regimen within recommended time guidelines, allowing a two month grace
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period (i.e., within 4 months after the first shot or 6 months after the second shot at the time
of the follow-up interview) [14].
2.3. Data analysis
We calculated frequencies of reported pain or discomfort for all three adolescent vaccines
and reported syncope following HPV vaccination. We analyzed the “pain level comparison”
variables comparing reported pain from HPV vaccine with that from tetanus booster and
meningococcal vaccines using the sign test. We then analyzed the dichotomous pain
variables (any pain or no pain) using McNemar's chi-square test to calculate odds ratios
(ORs) and confidence intervals (CIs). Binary logistic regression was used to examine the
bivariate associations between the two dichotomous HPV vaccine pain variables (at the time
of injection and in the hours and days afterwards) and completion of the HPV vaccine
regimen. Data were unweighted and analyzed using Intercooled Stata Version 10.1 (College
Station, TX). All statistical tests were two-tailed, using a critical alpha of 0.05.
3. Results
3.1. Reported vaccine pain
The majority of parents (65%, 148/229) reported their daughters experienced pain or
discomfort following receipt of HPV vaccine, with pain more commonly reported at the
time of injection (58%, 133/229) than in the hours and days following vaccination (45%,
102/229) (Table 2). Few parents reported their daughters experienced moderate or severe
pain at the time of injection (10%, 2%) or in the hours or days following vaccination (7%,
less than 1%). Reported pain from HPV vaccine in the hours and days after injection lasted a
median of 48 h (range = 1–336 h). No parents reported syncope among their daughters
following HPV vaccination, but eight (3%) reported their daughters felt dizzy or light-
headed.
Most parents reported their daughters experienced some pain or discomfort from tetanus
booster vaccine (84%, 174/206) and meningococcal vaccine (73%, 84/115). For both
vaccines, more parents reported their daughters experienced pain at the time of injection
(tetanus booster vaccine = 81%, meningococcal vaccine = 71%) than in the hours and days
following vaccination (tetanus booster vaccine = 67%, meningococcal vaccine = 46%).
3.2. Reported HPV vaccine pain vs. tetanus and meningococcal vaccine pain
Among parents whose daughters had received both HPV and tetanus booster vaccines,
parents were more likely to report a lower level of pain from HPV vaccine than from tetanus
booster vaccine at both the time of injection (p < 0.001) and in the hours and days after
vaccination (p < 0.001) (Fig. 1). Of parents whose daughters had received both HPV and
meningococcal vaccines, parents were more likely to report a lower level of pain from HPV
vaccine than from meningococcal vaccine at the time of injection (p = 0.003) but not in the
hours and days following vaccination (p = 1.00).
Comparing the dichotomous pain variables for these three adolescent vaccines yielded a
similar pattern of findings. More parents reported their daughters experienced pain from
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tetanus booster vaccine at the time of injection (83%, 154/186) than from HPV vaccine
(62%, 116/186) (OR = 6.43, 95% CI: 2.88–16.90, p < 0.001) among those whose daughters
had received both vaccines. A higher proportion of parents also reported their daughters
experienced pain from tetanus booster vaccine (70%, 133/191) than from HPV vaccine
(45%, 85/191) (OR = 4.43, 95% CI: 2.45–8.57, p < 0.001) in the hours and days following
vaccination. Among parents whose daughters had received both HPV and meningococcal
vaccines, more reported their daughters experienced pain from meningococcal vaccine at the
time of injection (74%, 77/104) than from HPV vaccine (59%, 61/104) (OR = 3.29, 95% CI:
1.36–9.07, p = 0.005). No difference was found for reported pain in the hours and days
following meningococcal and HPV injections (49%, 50/103 vs. 46%, 47/103) (OR = 1.20,
95% CI: 0.57–2.56, p = 0.728). Sensitivity analyses stratifying by daughter's age and
number of HPV vaccine doses received confirmed the robustness of our findings (data not
shown).
3.3. Reported HPV vaccine pain vs. all other vaccine pain
Most parents said HPV vaccine caused their daughters the same amount of pain or
discomfort at the time of injection compared to all other vaccines received (69%, 159/229).
Some parents said their daughters experienced less pain from HPV vaccine compared to all
other vaccines at the time of injection (17%, 38/229), while even fewer said it caused more
pain (12%, 27/229). Reports of pain or discomfort in the hours and days after vaccination
followed the same pattern (same pain: 62%, 142/229; less pain: 25%, 58/229; and more
pain: 11%, 25/229).
3.4. Influence of HPV vaccine pain on vaccine regimen completion
Reported pain from HPV vaccination did not influence timely uptake of subsequent doses of
HPV vaccine. Parents of daughters who had completed the three dose series (or were within
recommended time guidelines to do so) reported pain or discomfort at the time of injection
nearly as often as parents whose daughters were late for their second or third dose (62%,
114/185 vs. 68%, 19/28) (OR = 0.76, 95% CI: 0.33–1.77, p = 0.53). Similarly, reported pain
or discomfort in the hours and days after vaccination was equally common among parents
whose daughters were within and not within recommended time guidelines for completing




Anecdotal accounts and national media coverage have suggested that severe pain at the
injection site and syncope are particularly common adverse events following HPV
vaccination [4–6]. While many parents in our study reported their daughters experienced
pain or discomfort after receiving HPV vaccine, the reported pain was less frequent and less
severe than that associated with other adolescent vaccines and did not affect completion of
the HPV vaccine regimen. To our knowledge, this study is the first to examine HPV
vaccine-related pain outside the context of a clinical vaccine efficacy trial and the first to
compare reported pain from HPV vaccine with pain from other adolescent vaccines.
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A majority of parents reported their daughters experienced pain or discomfort after receiving
HPV vaccine, as well as after receiving meningococcal or tetanus booster vaccines.
Reported pain in our community-based study was similar to previous clinical trials involving
these vaccines (HPV vaccine: 73–84% [7–9]; tetanus booster vaccine: 64–87% [17,20,21];
meningococcal conjugate vaccine: 69% [18]).
Of greater interest, most parents indicated their daughters experienced the same amount of
pain or less pain from HPV vaccine than with tetanus booster and meningococcal vaccines.
Comparatively few parents indicated their daughter experienced more pain from HPV
vaccine. Similar results were obtained when parents were asked to compare HPV vaccine to
all other vaccines their daughters had received. Reported pain from HPV vaccine also did
not appear to influence completion of the HPV vaccine regimen, which is consistent with the
findings of HPV vaccine clinical trials in which few participants discontinued the vaccine
regimen due to adverse reactions [7].
Few parents reported their daughters experienced dizziness after receiving HPV vaccine and
none reported syncope, which is reassuring given the concerns about syncope after HPV
vaccine receipt. These findings support both results from HPV vaccine clinical trials (4%
reported dizziness) [7] and evidence suggesting reports of serious occurrences of syncope
are not common following HPV vaccination [13,22]. However, we acknowledge that a much
larger sample size would be required to assess increased risk of syncope following HPV
vaccination adequately.
4.2. Strengths and limitations
Our study's strengths include assessment of a sizable sample of parents with daughters in the
recommended age range for HPV vaccine and other adolescent vaccines, a good response
rate, and examination of pain at both the time of injection and in the hours and days after
vaccination.
As previously mentioned, our study's main limitation was reliance on parental recall of
daughters' vaccination experiences. However, we believe the pain comparisons were valid
because the reported pain levels for each of the three vaccines were comparable to previous
studies, several of which used the same categories in measuring pain level [7,17,18]. We did
not collect vaccination dates for tetanus booster and meningococcal vaccines, so we do not
know when they were received in relation to HPV vaccine. We were not able to examine
dose-specific reports of pain, as all HPV vaccine pain items referred to any doses received
so far. Clinical trials have, however, showed that reported pain was almost equivalent across
the threes doses [7]. Our study focused on common adolescent vaccines, but findings could
differ if HPV vaccine were compared to other vaccines with lower levels of reactogenicity.
As our study included parents from one area of North Carolina who had a telephone and
spoke English, the generalizability of the findings is not yet known.
4.3. Conclusions
We believe our results have important public health implications. Future programs designed
to increase initiation and completion of the HPV vaccine regimen may inform parents,
daughters, and healthcare providers that pain from HPV vaccination has been reported by
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parents as being similar to or less than pain from other adolescent vaccines their daughters
have received. Such information can help alleviate concerns and fears regarding adverse
events following HPV vaccination not only among parents but also healthcare providers, as
both groups have expressed concern over possible side effects from the vaccine [3,23–25].
An important next step is to prospectively assess adolescent girls' pain reports from HPV
and other vaccines and associated vaccine regimen completion to confirm our findings.
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Parents' reports of daughters' pain level from HPV vaccine compared to pain levels from
tetanus booster and meningococcal vaccines. Note: Bars indicate the standard errors of the
proportions. Pain levels (no pain, mild, moderate, or severe pain) reported for HPV vaccine
were compared with those reported for tetanus booster and meningococcal vaccines in
creating the three categories of “less pain from HPV vaccine,” “same level of pain,” and
“more pain from HPV vaccine.” HPV: human papillomavirus.
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Table 1
Characteristics of parents and their daughters who had received at least one dose of human papillomavirus
(HPV) vaccine (n = 229).
Mean (SD)
Daughter characteristics Age (years) 16.4 (2.3)
Parent characteristics Age (years) 45.2 (6.4)
n(%)
Sex
 Female 218 (95)
 Male 11 (5)
Race/ethnicity
 White, non-Hispanic 177 (77)
 African American, non-Hispanic 39 (17)
 Other 13 (6)
Marital status
 Married/living as married 198 (86)
 Other (divorced, widowed, separated, never married) 31 (14)
Education level
 Some college or more 200 (87)
 High school or less 29 (13)
Annual household income
 Less than $60,000 82 (36)
 $60,000 and over 136 (59)
 Missing 11 (5)
Residence type
 Urban 108 (47)
 Rural 121 (53)
Note. SD: standard deviation.
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Table 2
Parents' reports of daughters' pain or discomfort from HPV, tetanus booster, and meningococcal vaccines.





Pain from HPV vaccine at time of
injection 80 (35) 104 (45) 24 (10) 5 (2) 13 (6) 3 (1)
Pain from tetanus booster vaccine
at time of injection 35 (17) 102 (50) 58 (28) 6 (3) 1 (<1) 4 (2)
Pain from meningococcal vaccine
at time of injection 28 (24) 66 (57) 16 (14) 0 (0) 2 (2) 3 (3)
Pain from HPV vaccine in hours
and days after 116 (51) 85 (37) 16 (7) 1 (<1) 7 (3) 4 (2)
Pain from tetanus booster vaccine
in hours and days after 62 (30) 92 (45) 42 (20) 4 (2) 3 (1) 3 (1)
Pain from meningococcal vaccine
in hours and days after 56 (49) 48 (42) 5 (4) 0 (0) 4 (3) 2 (2)
Note. Row percents may not sum to 100% due to rounding. HPV: human papillomavirus.
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